Most Read Articles
Rachel Soon, 07 Jun 2018

For the first time, healthcare professionals may now refer to the Malaysian Clinical Practice Guidelines on the Management of Diabetes in Pregnancy for treatment options.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Elvira Manzano, 01 Jun 2018
The use of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in the phase III DERIVE* study.
Dr Joslyn Ngu, Rachel Soon, 08 Jun 2018

In conjunction with World No-Tobacco Day 2018, MIMS speaks to Professor Dr. Mohamad Haniki Nik Mohamed about his work in expanding the MOH's integrated quit-smoking service, mQuit.

Prereactivation propranolol reduces PTSD symptoms

14 May 2018
Mind training is the key to prevent PTSD among emergency responders handling trauma cases

Prereactivation propranolol, a treatment protocol suggested by reconsolidation theory, shows potential in reducing symptoms of post-traumatic stress disorder (PTSD), a recent study has shown.

There was a statistically significant 11.50 estimated group difference in post-treatment Clinician-Administered PTSD Scale (CAPS) score, adjusted for pretreatment values (analysis of covariance). The within-group pre- to post-treatment effect sizes (Cohen’s d) were 1.76 and 1.25 for propranolol and placebo, respectively.

The mixed linear model’s estimated time-by-group interaction for the patient-rated PTSD Checklist–Specific (PCL-S) generated an average decrease of 2.43 points per week. The total significant difference was 14.58 points above that of placebo. The pre- to post-treatment effect sizes were 2.74 and 0.55 for propranolol and placebo, respectively.

Analyses per protocol revealed similar significant results for both outcomes.

A total of 60 adults diagnosed with long-standing PTSD were included in this 6-week, double-blind, placebo-controlled, randomized clinical trial. The investigators administered propranolol or placebo 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks.

They hypothesized a significant treatment effect of trauma reactivation with propranolol vs trauma reactivation with placebo in reducing PTSD symptoms on both the CAPS and PCL-S in an intention-to-treat analysis.

“Replication studies using a long-term follow-up in various trauma populations are required,” the investigators said.

A noradrenergic beta-receptor, propranolol has been used in this study as a putative reconsolidation blocker to reduce PTSD symptoms, they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 07 Jun 2018

For the first time, healthcare professionals may now refer to the Malaysian Clinical Practice Guidelines on the Management of Diabetes in Pregnancy for treatment options.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Elvira Manzano, 01 Jun 2018
The use of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in the phase III DERIVE* study.
Dr Joslyn Ngu, Rachel Soon, 08 Jun 2018

In conjunction with World No-Tobacco Day 2018, MIMS speaks to Professor Dr. Mohamad Haniki Nik Mohamed about his work in expanding the MOH's integrated quit-smoking service, mQuit.